Floatz logo

AMIFAMPRIDINE

Spinal Muscular Atrophy, Type III

Catalyst Pharmaceuticals, Inc.Small moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

5 Active assets in the Spinal Muscular Atrophy, Type III cohort.

Asset / SponsorPhaseRating
Apitegromab
Scholar Rock, Inc.
Phase 3BB
Pyridostigmine
UMC Utrecht
Phase 2B
Non-Replicating Recombinant Self-Complementary (Sc) Adeno-Associated Virus Serotype 9 (Aav9) Vector Containing The Cdna Of The Survival Of Motor Neuron 2 (Smn2) Gene Under The Control Of The Hybrid Cytomegalovirus (Cmv) Enhancer/Chicken Beta-Actin Promoter (Cba)
Novartis Gene Therapies
Phase 3B
Olesoxime, E-
Hoffmann-La Roche
Phase 2B
Risdiplam
Scholar Rock, Inc.
Phase 2CCC
Nusinersen
Scholar Rock, Inc.
Phase 2CCC
Sodium Phenylbutyrate
Westat
Phase 1/2CCC
gc101
GeneCradle Inc
Phase 1/2CC

Same molecule, other indications

AMIFAMPRIDINE is also rated in:

chronic inflammatory demyelinating polyradiculoneuropathyDormant
BB
Indicative · Phase 3
64 / 100
View asset →
multiple sclerosisDormant
B
Indicative · Phase 3
59 / 100
View asset →
spinal muscular atrophyDormant
B
Indicative · Phase 2
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →